Video
Dr. Ramnaraign on Sequencing IO and TKI Combinations in Metastatic RCC
Author(s):
Brian Ramnaraign, MD, discusses sequencing immunotherapy and tyrosine kinase inhibitor combinations in metastatic renal cell carcinoma.
Brian Ramnaraign, MD, assistant professor of medicine, Division of Hematology and Oncology, University of Florida College of Medicine, discusses sequencing immunotherapy (IO) and tyrosine kinase inhibitor (TKI) combinations in metastatic renal cell carcinoma (mRCC).
When treating patients with mRCC, the preference of a patient and individual comorbidities must factor into therapy decisions, Ramnaraign says. There have been no head-to-head studies looking at the spanning treatment regimens in this space, and drawing conclusions from cross-trial comparisons should be done with a grain of salt, Ramnaraign adds.
When considering utilizing an IO combination compared with an IO and TKI combination, it is possible to begin with an IO and TKI combination in all risk categories, Ramnaraign continues. IO/TKI combinations have demonstrated higher objective response rates and cognitive load response across patients with varying levels of risk vs IO-IO combinations, Ramnaraign concludes.
